Drug Trial Radar · NCT04711226
Safety, Tolerability and Efficacy of Immunomodulation With AT-1501 in Islet Cell Transplantation
Last checked: Nov 19, 2026Latest source record: Aug 10, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Feb 19, 2021
Primary completion
Jun 2024
Study completion Jun 2026
Sponsor
- Lead sponsor
- Anelixis Therapeutics, LLCIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the safety, tolerability and efficacy of AT-1501 in an immunomodulation regimen in adult patients with T1D undergoing an islet cell transplant.
Conditions
- Type 1 Diabetes Mellitus
Interventions
AT-1501Drug
AT-1501 IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety- Adverse Events (AE) and Adverse Events of Special Interest (AEoSI)Time frame: Accessed from date of transplant through 1 year post transplant for approximately 2 years
- Efficacy- Insulin independenceTime frame: Days 75 , Day 365 post-first transplant, and final transplant and 1 year after discontinuation of AT-1501
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Alberta
Edmonton, Alberta, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.